National Pharmaceutical Pricing Authority

(Published in Part II, Section 3, Sub-section (ii) of

the Gazette of India, Extraordinary, dated the 1^st October, 2008)

Government of India

Ministry of Chemicals and Fertilizers

National Pharmaceutical Pricing Authority

New Delhi, the 1^st October, 2008

ORDER

S.O. 2352(E)- In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (6) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Shreya Life Sciences Pvt. Ltd.

TABLE

Sl. No.	Name of the formulation	Pack Size	Existing Retail Price Excise (Rs.)	Retail Price without Excise Duty Sales Tax /VAT and Local Tax, if any (Rs.)	Equivalent MRP* inclusive of all taxes (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Recosulin M30 100iu/ml Insulin Injection Isophane Ph Eur (Recombinant Human Monocomponent Insulin (Isophane) Each ml contains 30/70 of Insulin Ph. Eur & Isophane Human Insulin 100iu M-cresol USP – 1.5mg Phenol Ph Eur – 0.65mg Excipients – QS Batch No. 61010508 & 61011007 Qty. 15000 Cartridges Imported	3ml Cartridge	203.11	197.23	205.12
2	Recosulin R 100iu/ml Insulin Injection Isophane Ph Eur (Recombinant Human Monocomponent Insulin (Regular) Each ml contains Human Insulin Ph Eur – 100iuM-cresol USP – 3mg Excipients – QS Batch No. 57010408 / Qty. 5000 Cartridges Imported	3ml Cartridge	218.90	197.23	205.12
3	Recosulin N100iu/ml Insulin Injection Isophane Ph Eur (Recombinant Human Monocomponent Insulin (Isophane) Each ml contains Isophane Human Insulin Ph Eur – 100iu M-cresol USP – 1.5mgPhenol Ph Eur – 0.65mgExcipients – QSBatch No. 58010408 / Qty. 5000 Cartridges Imported	3ml Cartridge	218.90	197.23	205.12
4	Lupisulin- R (Plain) 40 IU/ML Each ml contains Insulin Human (r DNA origin ) USP 40 IUMetacresol USP 3.0mg(as preservative) Water for injection I.P	10ml Vial	–	129.00	134.16
5	Lupisulin- N (NPH) 40 IU/ML Each ml contains Insulin Human (r DNA origin ) USP 40 IU Metacresol USP 1.5mg (as preservative) Phenol IP 0.65 mg (as preservative) Water for injection I.P	10ml Vial	–	130.42	135.64
6	Lupisulin- M 30 (30/70) 40 IU/ML Each ml contains Insulin Human (r DNA origin ) USP 40 IU(30% Regular Insulin Human neutral and70% Isophane Insulin)Metacresol USP 1.5mg (as preservative) Phenol IP 0.65 mg (as preservative)Water for injection I.P	10ml Vial	–	130.08	135.28
7	Lupisulin- M 50 (50 / 50) 40 IU/ML Each ml contains Insulin Human (r DNA origin ) USP 40 IU(50% Regular Insulin Human neutral and 50% Isophane Insulin)Metacresol USP 1.5mg (as preservative) Phenol IP 0.65 mg (as preservative)Water for injection I.P	10ml Vial	–	129.81	135.00

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a) The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.

(b) The companies / manufacturers may added taxes only if they have paid actually to the Government on the price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.

(c) For different packing material used or any special feature claimed, companies are required to approach NPPA for approval/fixation of specific prices.

(d) The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.

(e) These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.

(f) These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.

PN/104/2008/F

F. No. 8(13)/2008/D.P./NPPA-Div.-II

(RAJEEV WADHAWAN)

Deputy Director

Last Page Updated: 01-06-2019

Note :Website Content Managed by National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Designed, Developed and Hosted by National Informatics Centre Services Inc.(NICSI)